Basilea presents new research data on oncology drug candidate
BAL27862 at international cancer confe
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Basel, Switzerland, November 19, 2009 - Basilea Pharmaceutica Ltd.(SIX:BSLN) presents new research data on its innovative antitumordrug candidate BAL27862 at the international conference on MolecularTargets and Cancer Therapeutics in Boston (MA). BAL27862 is a novel,intravenous and orally bioavailable small molecule. It disrupts themicrotubule network, a well established intracellular target inoncology, through a unique mechanism of action. The new data suggestthat BAL27862 has the potential for a distinct anticancer profile ina wide range of cancer types, including those resistant to currenttreatment options.Despite progress in the development of agents with antitumoractivity, cancer remains a significant challenge in healthcare. Thereis a continuing medical need for novel agents with new mechanisms ofaction that overcome drug resistance in cancer therapy.BAL27862 - active against tumors unresponsive to standard drugsBAL27862 is a novel, intravenous and orally bioavailable smallmolecule with a unique mechanism of action against microtubules, awell established intracellular target in oncology. BAL27862 targetstumor cells by disrupting the microtubule scaffold, which isessential for cell division. Preclinical activity has been shownagainst a broad range of tumor types as well as in tumor models knownto be unresponsive to standard therapeutics, including marketedmicrotubule-targeting agents such as the taxanes. The properties ofBAL27862 allow intravenous administration in the absence ofsolubilizing excipients that are known to be associated with sideeffects.BAL27862 - unique mode of actionNew research data presented at the international conference onMolecular Targets and Cancer Therapeutics reveal that BAL27862 hasimpressive activity against a panel of non small cell lung cancercell lines, including patient-derived tumor cells resistant topaclitaxel, a widely-used cancer drug inhibiting microtubulebreak-down during cell division. A detailed analysis demonstrates adominant effect of BAL27862 on microtubules that is clearly distinctfrom that seen with microtubule-targeting agents currently used inclinical practice (F. Bachmann et al., Poster C 229). Pharmacokineticanalyses demonstrate that BAL27862 is efficiently distributed totissues in a mouse model of human cancer, with excellent tumor aswell as brain penetration. Potent activity was observed againstglioblastoma cell lines associated with a dramatic increase in tumorcell death (A. Schmitt-Hoffmann et al., Poster C 233). These datasuggest that BAL27862 has the potential for a distinct anticancerprofile and support further evaluation for the treatment of a rangeof tumors, including brain cancers.Posters on BAL27862 displayed at the international conference onMolecular Targets and Cancer Therapeutics 2009BAL27862: A novel anticancer agent that dissociates microtubules andcreates a distinct cellular phenotype - F. Bachmann, K. Burger, J.Pohlmann, L. Kellenberger and H. Lane; Poster C 229BAL27862: A unique microtubule-targeted agent with a potential forthe treatment of human brain tumors - A. Schmitt-Hoffmann, D. Klauer,K. Gebhardt, A. Brendle, P. Fullhardt, P. Hargreaves, C. Bucher, C.Schläfle, J. Spickermann, R. Defoin, K. Burger, V. Vuong, M. Pruschy,F. Bachmann and H. Lane; Poster C 233The conference is hosted by the American Association for CancerResearch, the U.S. National Cancer Institute and the EuropeanOrganization for Research and Treatment of Cancer.About BasileaBasilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland,and listed on the SIX Swiss Exchange (SIX:BSLN). Basilea's integratedresearch and development operations are currently focused on newantibacterial, antifungal and oncology agents to fight drugresistance and on the development of dermatology drugs. Basilea'sproducts are targeted to satisfy high medical and patient needs inthe hospital and specialty care setting.The company owns a diversified portfolio including two commercializeddrugs (Toctino®, ZEFTERA(TM) / Zevtera(TM)) and one investigationaldrug (isavuconazole) in phase III clinical development. Toctino®(alitretinoin) is marketed in Denmark, France, Germany and the UnitedKingdom. It is approved in Austria, Belgium, Canada, Finland,Luxemburg, the Netherlands, Spain and Switzerland. Alitretinoin hasbeen recommended for approval in Italy and is under regulatory reviewin 15 additional European countries. Furthermore a phase III clinicaltrial on alitretinoin for the treatment of severe chronic hand eczemais ongoing in the U.S.Ceftobiprole is marketed in Canada under the brand name ZEFTERA(TM)and in Switzerland under Zevtera(TM). Ceftobiprole is underregulatory review in the U.S., in the EU and several other countries.The company has set up commercial organizations in Canada, Denmark,France, Germany and the UK, while it is building sales and marketingorganizations in other countries to commercialize alitretinoin and toco-promote ceftobiprole, subject to approval.DisclaimerThis communication expressly or implicitly contains certainforward-looking statements concerning Basilea Pharmaceutica Ltd. andits business. Such statements involve certain known and unknownrisks, uncertainties and other factors, which could cause the actualresults, financial condition, performance or achievements of BasileaPharmaceutica Ltd. to be materially different from any futureresults, performance or achievements expressed or implied by suchforward-looking statements. Basilea Pharmaceutica Ltd. is providingthis communication as of this date and does not undertake to updateany forward-looking statements contained Therein as a result of newinformation, future events or otherwise.For further information, please contact:+--------------------------------------------------------------+| Media Relations | Investor Relations ||-----------------------------+--------------------------------|| Adesh Kaul | Barbara Zink, Ph.D. || Head Public Relations & | Head Corporate Development || Corporate Communications | || +41 61 606 1460 | +41 61 606 1233 || media_relations(at)basilea.com | investor_relations(at)basilea.com |+--------------------------------------------------------------+This press release can be downloaded from www.basilea.com.The press release can also be downloaded from the following link:http://hugin.info/134390/R/1356001/329371.pdf --- End of Message ---Basilea Pharmaceutica AGGrenzacherstrasse 487
P.O Box Basel SwitzerlandWKN: A0B9GA; ISIN: CH0011432447; Index: SLIFE, SMCI, SPI, SPIEX, SBIOM;Listed: Main Market in SIX Swiss Exchange;
Datum: 19.11.2009 - 07:15 Uhr
Sprache: Deutsch
News-ID 8602
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 462 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea presents new research data on oncology drug candidate
BAL27862 at international cancer confe"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
